We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

54 hedge funds and large institutions have $128M invested in Xeris Biopharma Holdings in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,600% more call options, than puts

Call options by funds: $194K | Put options by funds: $2K

130% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 10

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 53 → 54 (+1)

1.07% less ownership

Funds ownership: 66.37% → 65.31% (-1.1%)

27% less capital invested

Capital invested by funds: $176M → $128M (-$48.1M)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
23
Reduced
10
Closed
8
Calls
$194K
Puts
$2K
Net Calls
+$192K
Net Calls Change
+$186K

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$18.2M
2
Blackstone Inc
Blackstone Inc
New York
+$3.72M
3
DM
Deerfield Management
New York
+$2.27M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$2.24M
5
Millennium Management
Millennium Management
New York
+$644K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.8M
2
EGM
Engineers Gate Manager
New York
-$199K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$197K
4
MIM
MetLife Investment Management
New Jersey
-$138K
5
JG
Jefferies Group
New York
-$115K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Redmile Group
California
$21.2M – – –
DM
2
Deerfield Management
New York
$18.2M +$2.27M +274,625 +12%
Citigroup
3
Citigroup
New York
$15.5M +$18.2M +2,198,541 +66,663%
BlackRock
4
BlackRock
New York
$15.5M +$541K +65,498 +3%
ACH
5
ArrowMark Colorado Holdings
Colorado
$13.6M +$2.24M +271,886 +16%
Vanguard Group
6
Vanguard Group
Pennsylvania
$9.29M +$194K +23,531 +2%
Invesco
7
Invesco
Georgia
$7.05M – – –
CLCM
8
Crawford Lake Capital Management
New Jersey
$4.16M +$599K +72,493 New
State Street
9
State Street
Massachusetts
$3.53M +$280K +33,950 +7%
Blackstone Inc
10
Blackstone Inc
New York
$3.17M +$3.72M +450,000 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.5M +$132K +15,952 +5%
Northern Trust
12
Northern Trust
Illinois
$2.13M -$30.3K -3,674 -1%
Federated Hermes
13
Federated Hermes
Pennsylvania
$2.12M – – –
Millennium Management
14
Millennium Management
New York
$1.21M +$644K +77,982 +83%
N
15
Nuveen
North Carolina
$865K -$9.22K -1,117 -0.9%
PPA
16
Parametric Portfolio Associates
Washington
$662K +$238K +28,849 +44%
IWM
17
IHT Wealth Management
Illinois
$639K +$278K +33,647 +59%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$588K +$54.9K +6,648 +9%
Wells Fargo
19
Wells Fargo
California
$486K +$149K +18,065 +35%
Charles Schwab
20
Charles Schwab
California
$477K – – –
MCM
21
Moore Capital Management
New York
$353K – – –
GCP
22
GSA Capital Partners
United Kingdom
$335K +$393K +47,578 New
ECM
23
ExodusPoint Capital Management
New York
$331K +$388K +47,000 New
Morgan Stanley
24
Morgan Stanley
New York
$315K +$305K +36,905 +468%
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$309K +$19.2K +2,327 +6%
1
2 3

XERS Hedge Fund Activity: Q4 2019 in Review

54 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2019, worth a combined $128M — down 27% from $176M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XERS positions and 8 closed out — a net gain of 1 holder — while 23 added to existing stakes and 10 trimmed.

The largest buyer was Citigroup, adding an estimated $18.2M. The largest seller was Fidelity Investments, exiting entirely with an estimated $39.8M sold.

  • 54 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2019, up from 53 in Q3 2019.
  • Funds reported $128M of Xeris Biopharma Holdings stock for Q4 2019, down 27% quarter-over-quarter.
  • 9 funds opened new Xeris Biopharma Holdings positions in Q4 2019 and 8 closed out, a net change of +1 holder.
  • The largest Xeris Biopharma Holdings buyer in Q4 2019 was Citigroup, an estimated $18.2M added.
  • The largest Xeris Biopharma Holdings seller in Q4 2019 was Fidelity Investments, an estimated $39.8M sold.

Based on aggregated 13F filings for Q4 2019.